LasR-IN-2, a compound that inhibits the activity of LasR, forms hydrogen bonding with the TRY-56 residue. It finds application in the study of bacterial infection, neutropenia, severe burns, and chronic lung disease in cystic fibrosis (CF) [1].

LasR-IN-2 (Compound 8a), over a concentration range of 4.68-150 μg/mL and an exposure period of 24 hours, effectively inhibits the growth of P. aeruginosa, as demonstrated by a decrease in bacterial propagation and a Minimum Inhibitory Concentration (MIC) value of 74.40 μM [1]. At a specific concentration of 18.5 μM for the same duration, LasR-IN-2 also suppresses biofilm formation, pyocyanin production, and rhamnolipids synthesis [1]. Furthermore, this compound impedes the proliferation of human dermal fibroblasts (HDFa) with an IC50 value of 102 μM after 24 hours of treatment, indicating its potent biocidal and cytotoxic effects [1].